Composition and method for treating penile erectile dysfunction

Details Composition and method for treating penile erectile dysfunction Composition and method for treating penile erectile dysfunction

1997-05-27

1999-08-24

Jarvis, William R. A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

514254, 514401, A61K 31557, A61K 31495, A61K 3150, A61K 31415

Patent

active

059425458

ABSTRACT:
A composition for the topical transdermal administration to the penis is based on prostaglandin E.sub.1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E.sub.1 active ingredient through the skin. Phentolamine or prazosin may be used in combination with prostaglandin E.sub.1.

REFERENCES:
patent: 4127118 (1978-11-01), Latorre
patent: 4311707 (1982-01-01), Birnbaum et al.
patent: 4801587 (1989-01-01), Voss et al.
patent: 4861764 (1989-08-01), Samour et al.
patent: 5059603 (1991-10-01), Rubin
patent: 5145852 (1992-09-01), Virag
patent: 5219885 (1993-06-01), Frolich et al.
patent: 5236904 (1993-08-01), Gerstenberg et al.
patent: 5242391 (1993-09-01), Place et al.
patent: 5256652 (1993-10-01), El-Rashidy
patent: 5270323 (1993-12-01), Milne, Jr. et al.
patent: 5336678 (1994-08-01), Cavallini
patent: 5380760 (1995-01-01), Wendel et al.
patent: 5399581 (1995-03-01), Laragh
patent: 5439938 (1995-08-01), Snyder et al.
patent: 5447920 (1995-09-01), Matsuda et al.
patent: 5451609 (1995-09-01), Bellamy et al.
patent: 5464868 (1995-11-01), Frolich et al.
patent: 5475535 (1995-12-01), Eckhardt
patent: 5482039 (1996-01-01), Place
patent: 5488059 (1996-01-01), Buhl
patent: 5492911 (1996-02-01), Stief
patent: 5527797 (1996-06-01), Eisenberg et al.
patent: 5565466 (1996-10-01), Gioco et al.
patent: 5583144 (1996-12-01), Kral et al.
patent: 5587167 (1996-12-01), Choi et al.
patent: 5594032 (1997-01-01), Gonzalez-Cadavid
patent: 5620980 (1997-04-01), Samour
Williams, et al., Skin Absorption Enhancers, Crit. Rev. Ther Drug Carrier Syst 1992(3-4) Abstract.
Monkhouse, et al., J. of Pharm. Sciences, vol. 62, No. 4, Apr. 1973.
Teagarden, et al., Dehydration Kinetics of Prostaglandin E.sub.1 in a Lipid Emulsion, Pharmaceutical Research, vol. 6, No. 3, 1989.
Stehle, et al., Journal of Pharmaceutical Sciences, vol. 66, No. 11, Nov. 1977.
Anderson, et al., Prodrugs and Their Topical Use, Topical Drug Bioavalability, Bioequivalence, and Penetration, Plenum Press, 1993.
Montorsi, et al., Pharmacological Management of Erectile Dysfunction, Drugs 50(3), 1995, pp. 465-479.
Fuhrman, et al., Pred. of Percutaneous Penetration, vol. 4B, 1996.
American Society of Andrology, 1995 Annual Meeting, Mar. 31-Apr. 4, 1995, Abstract re Induction of Erections in Anesthetized Cynomologus Monkeys.
American Society of Andrology, 1994 Annual Meeting, Mar. 4-7, 1994, Abstract re Treatment of Erectile Dysfunction in Men with Diabetes Mellitus.
Watkinson, et al., Aspects of the transdermal delivery of prostaglandins, Int. J. of Pharma. 74(1991) 229-236.
Kim and McVary, Topical prostaglandin-E1 for the treatment of erectile dysfunction, Journal of Urology, vol. 158, 1828-1830 (1995).
Kim, et al., Papaverine topical gel for treatment of erectile dysfunction, Journal of Urology, vol. 158, 361-385 (1995).
Gomaa, et al., Topical treatment of erectile dysfunction: randomised double blind . . . , British Med. Journal, 312:1512-1515 (1995).
Becher, et al., Abstract, A Double bind placebo controlled trial of topical prostaglandin E1 . . . , San Francisco, CA symposium (1997).
Linet, et al., Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction, New England J. of Medicine, 334(14):873-877, 1996.
Padma-Nathan, et al., Treatment of men with erectile dysfunction with transurethral alprostadil, New England J. of Medicine, 336(1):1-7, 1997.
Anderson, et al., Topical nitrate treatment of impotence, Annals of Pharmacotherapy, 27:1203-1205 (1993).
MacroChem Press Release, Mar. 5, 1996, "MacroChem Announces Initiation Of A Phase I/II Clinical Trial of a Topical Gel Containing Prostaglandin E1 . . . ".
MacroChem Press Release, May 14, 1996, "MacroChem Initiates Phase I/II Clinical Trial of Topical Formulation For Erectile Dysfunction".
MacroChem Press Release, Dec. 10, 1996, "MacroChem Announces Positive Results Attained in a Phase I/II Clinical Trial of Topical Gel For Erectile Dysfunction".

Affiliated with

Also associated with

Rating

Composition and method for treating penile erectile dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition and method for treating penile erectile dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating penile erectile dysfunction will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-467377